Alzheimer’s Disease Treatment Global Market Report 2021: COVID-19 Growth And Change To 2030
- September 2021 •
- 175 pages •
- Report ID: 6151672 •
- Format: PDF
The global alzheimer’s disease treatment market is expected to grow from $3.43 billion in 2020 to $3.76 billion in 2021 at a compound annual growth rate (CAGR) of 9.6%. The growth is mainly due to the companies resuming their operations and adapting to the new normal while recovering from the COVID-19 impact, which had earlier led to restrictive containment measures involving social distancing, remote working, and the closure of commercial activities that resulted in operational challenges. The market is expected to reach $5.91 billion in 2025 at a CAGR of 12%.
The global Alzheimer’s disease treatment market consists of sales of drugs used to treat Alzheimer’s disease.Alzheimer’s disease is a progressive neurological disorder causing degeneration of brain cells, resulting in dementia (a condition that causes a decline in thinking, behavioural and social skills).
The progression of this disease causes severe memory impairment and the person may lose the ability to carry out everyday tasks.
The Alzheimer’s disease treatment market covered in this report is segmented by drug class into cholinergic, memantine, combined drug, AChE inhibitors, immunoglobulins and by drug type into cholinesterase inhibitors, NMDA receptor antagonists.
The regions covered in this report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
Lack of techniques for diagnosing Alzheimer’s disease (AD) is expected to limit the growth of the global Alzheimer’s disease treatment market.There is no definitive blood test, brain scan, or physical exam to diagnose AD, and so many conditions can produce symptoms like dementia, which is the primary clinical symptom of AD, making the diagnosis complicated.
The lack of a single test for diagnosis, specialists such as neurologists, neuropsychologists, geriatricians and geriatric psychiatrists use a variety of approaches for diagnosis to confirm dementia, but it is still difficult to find the cause resulting in late diagnosis. Lack of proper and quick diagnosis for AD hampers the market growth as it leads to a reduced number of diagnosed cases and thereby reduces the consumption of AD drugs.
In January 2020, Biogen Inc., an American multinational biotechnology company, acquired Pfizer Inc. for an upfront payment of $75 million with up to $635 million in potential additional development and commercialization milestone payments. Through this acquisition, Biogen plans to develop the Phase 1 asset for the treatment of Sundowning in Alzheimer’s disease (AD) and Irregular Sleep Wake Rhythm Disorder (ISWRD) in Parkinson’s disease (PD). Pfizer Inc. is an American multinational pharmaceutical corporation engaged in the discovery, development and manufacture of healthcare products including medicines and vaccines.
The increasing cases of Alzheimer’s is a major factor contributing to the growth of the Alzheimer’s treatment market.Alzheimer’s is the most common type of dementia.
The USA Alzheimer’s Association expects that all the states in the US are projected to face a rise of at least 14% in the number of Alzheimer’s people between 2017 and 2025 due to the increase in the geriatric population.At the global level, the estimated new cases of Alzheimer’s is expected to grow by 35% to 615,000 by 2030, and by 110% to 959,000 by 2050.
Therefore, the increasing prevalence of Alzheimer’s disease is expected to drive the growth of the global Alzheimer’s disease treatment market.
Increasing R&D investments and collaborations due to the emerging technologies for the treatment is a key trend in Alzheimer’s disease (AD) treatment market.The Alzheimer’s Association is assisting with funds to researchers in search of innovative therapeutic approaches and seeks more government funding for Alzheimer’s studies.
Technologies such as ?-site amyloid precursor protein cleaving enzyme 1 (BACE1) inhibitors and anti-amyloid inhibitors are emerging in the AD market.For instance, Comentis and Astellas collaborated and entered the BACE inhibitor field on their peptidomimetic series.
Manufacturing companies such as AC Immune, Adamas Pharmaceuticals, INmune Bio, Intra-Cellular Therapies, vTv Therapeutics are more focused on R&D investments with their research molecules in the clinical trials to achieve a breakthrough for the treatment of AD.
The countries covered in the market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA.